August 2021 – pharma.markets

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

16/08/2021 MaP 0

Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust […]

Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines

05/08/2021 MaP 0

….. for Emergency Use Authorization of Novavax’ Recombinant Nanoparticle COVID-19 Vaccine – Novavax and Serum Institute of India file regulatory submissions to the Drugs Controller […]

Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination

05/08/2021 MaP 0

Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series Six-fold increase in cross-reactive functional antibodies […]

KalGene Pharmaceuticals Inc. an Alzheimer’s focused company using a next generation engineered drug candidate, has appointed new leadership

05/08/2021 MaP 0

Mr. Anthony J. Giovinazzo joins as Executive Chairman; and Dr. Nickolay V. Kukekov, Ph.D. as President and CEO KalGene also announced that concurrent with the […]

BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform

04/08/2021 MaP 0

and Manufacturing Facility in Gaithersburg, Maryland The acquisition strengthens BioNTech’s cell therapy pipeline by accelerating the individualized solid tumor Neoantigen TCR cell therapy research and […]